Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib


Studies in Advanced NSCLC of Maintenance Pemetrexed and Erlotinib and of BIBW 2992 or MetMAb Targeted Therapy for Acquired Resistance to Erlotinib and Gefitinib
Slides from presentations at ASCO 2011 and comments from Edward S Kim, MD and Thomas J Lynch Jr, MD

Janjigian YY et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Proc ASCO 2011;Abstract 7525.

Dr Lynch is the Jonathan and Richard Sackler Professor of Internal Medicine, Director of the Yale Cancer Center and Physician-in-Chief at Smilow Cancer Hospital at Yale New Haven in New Haven, Connecticut.